Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jun 14:10:1178153.
doi: 10.3389/fcvm.2023.1178153. eCollection 2023.

Plasma osteoprotegerin predicts adverse cardiovascular events in stable coronary artery disease: the PEACE trial

Teng Ma #  1 , Jian Zhao #  2 , Yechao Yan #  1 , Junying Liu #  1 , Jie Zang  1 , Yaqi Zhang  1 , Kun Ruan  1 , Hong Xu  1 , Wan He  3
Affiliations

Plasma osteoprotegerin predicts adverse cardiovascular events in stable coronary artery disease: the PEACE trial

Teng Ma et al. Front Cardiovasc Med. .

Abstract

Background: Osteoprotegerin (OPG) is a secretory glycoprotein and participates in the progression of atherosclerotic lesions. We aim to explore the relationship between OPG and the prognosis of coronary artery disease (CAD).

Methods: Plasma OPG concentrations were measured in 3,766 patients with stable CAD enrolled in the PEACE trial. The PEACE trial (NCT00000558) group followed up the patients and examined their future clinical outcomes.

Results: In summary, 208 (5.5%) primary outcomes occurred, 295 patients (7.8%) died from all-cause death, 128 (3.4%) died from cardiovascular causes, and 94 (2.5%) experienced heart failure during a median follow-up of 1,892 days. In addition, we found that higher plasma levels of OPG were associated with a higher incidence of all-cause death, cardiovascular death, and heart failure, even after adjusting clinical cofounders.

Conclusion: It was demonstrated that elevated plasma OPG levels were associated with an increased incidence of all-cause death, cardiovascular death, and heart failure in patients with stable CAD.

Systematic review registration: https://clinicaltrials.gov/ct2/show/NCT00000558?term=NCT00000558&draw=2&rank=1, identifier: NCT00000558.

Keywords: biomarkers; coronary artery disease; heart failure; osteoprotegerin (OPG); prognostic model.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The handling editor SB declared a past co-authorship with the author MT.

Figures

Figure 1
Figure 1
Survival regarding the primary endpoint (A. Cardiovascular death and congestive heart failure) and the secondary endpoint (B. All cause death; C. Cardiovascular death; D. Congestive heart failure) stratified according to the tertile distribution of OPG.
Figure 2
Figure 2
Survival of the primary endpoint (cardiovascular death and congestive heart failure) stratified by median baseline OPG and NT-proBNP levels. Kaplan–Meier analysis stratified by median baseline OPG and NT-proBNP levels. Baseline median OPG was 2.18 ng/ml; the median level for NT-proBNP was 139 pg/ml. “High” indicates values above the median and “low” values below the median.
See this image and copyright information in PMC

References

    1. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Lüthy R, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. (1997) 89:309–19. 10.1016/s0092-8674(00)80209-3 - DOI - PubMed
    1. Yun TJ, Chaudhary PM, Shu GL, Frazer JK, Ewings MK, Schwartz SM, et al. OPG/FDCR-1, a TNF receptor family member, is expressed in lymphoid cells and is up-regulated by ligating CD40. J Immunol. (1998) 161:6113–21. 10.4049/jimmunol.161.11.6113 - DOI - PubMed
    1. Hofbauer LC, Shui C, Riggs BL, Dunstan CR, Spelsberg TC, O'Brien T, et al. Effects of immunosuppressants on receptor activator of NF-kappaB ligand and osteoprotegerin production by human osteoblastic and coronary artery smooth muscle cells. Biochem Biophys Res Commun. (2001) 280:334–9. 10.1006/bbrc.2000.4130 - DOI - PubMed
    1. Reid P, Holen I. Pathophysiological roles of osteoprotegerin (OPG). Eur J Cell Biol. (2009) 88:1–17. 10.1016/j.ejcb.2008.06.004 - DOI - PubMed
    1. Wang Y, Liu Y, Huang Z, Chen X, Zhang B. The roles of osteoprotegerin in cancer, far beyond a bone player. Cell Death Discov. (2022) 8:252. 10.1038/s41420-022-01042-0 - DOI - PMC - PubMed

Associated data